Demonstrated safety and tolerability were consistent with the systemic safety profile of oral olanzapine1
Treatment-emergent adverse events (AEs)2
MedDRA=Medical Dictionary for Regulatory Activities.
Please see additional Important Safety Information, including Boxed WARNING, below.
Overall tolerability: All 3 doses were similarly tolerated2
Discontinuations due to common AEs were 4%, as seen with placebo2
The most common AEs (≥5%): weight increased, somnolence, headache, constipation, and injection site reactions (induration, pain, erythema, pruritus, swelling)2
Serious AEs were reported in 1% of WELTRUZA-treated patients1
Weight gain and metabolic changes were observed and were consistent with the known safety profile of olanzapine, including clinically significant weight gain (≥7% of baseline body weight)2
Most injection site reactions were generally localized and occur early in treatment.2 They were self-limiting, declining over the long-term by 83% from the first (24%) to the fifth (4%) injection1,2
The overall safety profile of WELTRUZA was similar to that of oral olanzapine.1
up next
Dosing
Explore dosing options with no loading dose or oral supplementation required.
LEARN MOREReferences: 1. Data on file. Clinical Study Report. November 2025. Parsippany, NJ: Teva Neuroscience, Inc. 2. WELTRUZA™ (olanzapine) extended-release injectable suspension Current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.
